Atopic dermatitis and adherence to external therapy

Kochergin N.G.; Grigorian N.S.; Potekaev N.N.; Lytkina E.A.

doi:https://doi.org/

Kochergin N.G.

I.M. Sechenov Moscow Medical Academy

Grigorian N.S.

I.M. Sechenov First Moscow State Medical University, Moscow

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Lytkina E.A.

I.M. Sechenov First Moscow State Medical University, Moscow

Atopic dermatitis and adherence to external therapy

Authors:

Kochergin N.G., Grigorian N.S., Potekaev N.N., Lytkina E.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2010;8(5): 47‑50

Read: 1274 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kochergin NG, Grigorian NS, Potekaev NN, Lytkina EA. Atopic dermatitis and adherence to external therapy. Russian Journal of Clinical Dermatology and Venereology. 2010;8(5):47‑50. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

References:

Winterfield L.S., Menter A., Gordon K. et al. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005;64:87-90.
Feldman S.R. et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008;59:6:1009-1016.
Farmer K.C. Methods for measuring and monitoring medication regimen adherence in clinical trials and practice. Clin Ther 1999;21:1074-1090.
du Vivier A., Stoughton S. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975;111:581-583.
Miller J. et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids. J Am Acad Dermatol 1999;41:546-549.
Carroll C.L. et al. Adherence to topical therapy decreases during the course of an 8-week clinical trial. J Am Acad Dermatol 2004;51:212-216.
Basra M.K.A., Sue-Ho R., Finlay A.Y. Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007;156:528-538.
Basra M.K.A., Edmunds O., Salek M.S., Finlay A.Y. Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI). J Eur Acad Dermatol Venereol 2008;22:813-821.
de Prost Y., Wahn U. European experience with pimecrolimus cream in AD. JEADV 2001;15:Suppl 2:110.
Kochergin N.G. K probleme dermatozov vidimykh uchastkov kozhi. Estet med 2005;5:169-173.
Kochergin N.G. Atopicheskii dermatit, chuvstvitel'nye uchastki kozhi i vybor naruzhnoi terapii. Vestn dermatol venerol 2009;4:80-85.
Simon D. et al. Clinical effectiveness of pimecrolimus cream in different parts of the body in atopic dermatitis. Dermatology 2006;213:313-318.
Holmes M.W. et al. Cost-effectiveness of pimecrolimus cream in pediatric AD. Abstracts of 9th Congress of ESPD 2008;50.